Core Viewpoint - Aipeng Medical announced the approval of multiple proposals, including the "2025 Semi-Annual Report and its Summary," during the second meeting of the fourth board of directors held on August 27 [2] Group 1 - The board meeting focused on the review and approval of the 2025 semi-annual report [2] - The announcement indicates ongoing corporate governance and transparency efforts by the company [2]

Core Viewpoint - The financial performance of Aipeng Medical in the 2025 mid-year report shows significant declines in revenue and net profit, indicating potential challenges for the company moving forward [1][3]. Financial Performance Summary - The main revenue for the first half of 2025 was 159 million yuan, a year-on-year decrease of 11.31% [1][3]. - The net profit attributable to shareholders was -19.38 million yuan, a year-on-year decline of 317.9% [1][3]. - The non-recurring net profit was -20.14 million yuan, down 445.67% year-on-year [1][3]. - In Q2 2025, the single-quarter main revenue was 94.34 million yuan, an increase of 2.87% year-on-year [1][3]. - The single-quarter net profit attributable to shareholders was -1.73 million yuan, a decrease of 122.95% year-on-year [1][3]. - The single-quarter non-recurring net profit was -2.19 million yuan, down 153.38% year-on-year [1][3]. Key Financial Ratios - The debt ratio stood at 18.22% [1]. - Investment income was 1.01 million yuan, while financial expenses were 973,800 yuan [1]. - The gross profit margin was 63.22%, reflecting a year-on-year decrease of 7.28% [6]. - The return on equity was -2.81%, a year-on-year decline of 321.25% [6]. - Earnings per share were -0.15 yuan, down 317.70% year-on-year [6]. - The operating cash flow per share was -0.38 yuan, a significant decrease of 2327.07% year-on-year [6]. Shareholder Information - The top circulating shareholders include Wang Ningyu with 9.02 million shares (10.26%), Beijing Zhanghong Private Fund Management Co., Ltd. with 7.06 million shares (8.03%), and Zhang Zhihui with 3.29 million shares (3.75%) [10].

智通财经APP讯，爱朋医疗(300753.SZ)发布2025年半年度报告，该公司营业收入为1.59亿元，同比减少 11.31%。归属于上市公司股东的净亏损为1937.91万元。归属于上市公司股东的扣除非经常性损益的净 亏损为2014.19万元。基本每股亏损为0.1537元。 ...

江苏爱朋医疗科技股份有限公司 证券代码：300753 证券简称：爱朋医疗 公告编号：2025-045 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏爱朋医疗科技股份有限公司（以下简称"公司"）第四届董事会第二次会议通 知及会议材料于2025年8月16日以微信、电话、邮件形式向公司全体董事发出，会议于 2025年8月26日在上海市闵行区联航路1188号3号楼公司会议室以现场结合通讯的方式 召开。本次会议应出席董事8人，实际出席董事8人。会议由董事长王凝宇先生主持，部 分高级管理人员列席了本次会议，会议出席人数、召集、召开和表决程序符合《中华人 民共和国公司法》等相关法律法规以及《公司章程》的相关规定。 二、董事会会议审议情况 本次会议以记名方式投票表决，逐项审议以下议案： 1、审议通过《2025年半年度报告及其摘要》 董事会审议通过了《2025年半年度报告》《2025年半年度报告摘要》，认为公司2025 年半年度报告真实反映了公司2025年半年度的财务状况和经营成果，不存在虚假记载、 误导性陈述或重大 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section provides essential information, the report's structure, and definitions of key terms used throughout the document [Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The board and management affirm the report's accuracy, caution investors on forward-looking statements, and confirm no dividend or bonus share plans - The company's board of directors and senior management guarantee the truthfulness, accuracy, and completeness of the report content, with no false records, misleading statements, or major omissions[4](index=4&type=chunk) - The company's responsible person, head of accounting, and head of accounting department declare the financial report to be true, accurate, and complete[4](index=4&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[6](index=6&type=chunk) [Table of Contents](index=3&type=section&id=%E7%9B%AE%E5%BD%95) This section outlines the overall structure of the report, including eight main chapters covering various corporate and financial aspects [List of Documents for Reference](index=4&type=section&id=%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) This section lists the company's semi-annual report, financial statements, and other relevant documents available for inspection, specifying their storage location - Documents for reference include the semi-annual report signed by the legal representative, financial statements, original drafts of documents publicly disclosed on designated websites, and other relevant documents[10](index=10&type=chunk) - The documents for reference are stored at the east side of Yongtong Avenue, Rudong Economic Development Zone, Jiangsu Province[10](index=10&type=chunk) [Definitions](index=5&type=section&id=%E9%87%8A%E4%B9%89) This section defines key professional terms used in the report, covering company specifics, reporting periods, and medical device-related terminology - The reporting period refers to January 1, 2025, to June 30, 2025[12](index=12&type=chunk) - Medical devices are defined as instruments, equipment, appliances, in vitro diagnostic reagents and calibrators, materials, and other similar or related articles, including necessary computer software, used directly or indirectly on the human body[12](index=12&type=chunk) - Brain-Computer Interface (BCI) refers to a direct communication channel established between a biological brain and intelligent machines, capable of interpreting brain signals, controlling external devices, and encoding information into the brain[13](index=13&type=chunk) [Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides the company's basic information and a summary of its key financial performance and position during the reporting period [Company Profile](index=7&type=section&id=%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) This section provides basic information about Jiangsu Apon Medical Technology Co., Ltd., including stock details and legal representative Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Apon Medical | | Stock Code | 300753 | | Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Jiangsu Apon Medical Technology Co., Ltd. | | Legal Representative | Wang Ningyu | [Contact Persons and Information](index=7&type=section&id=%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) This section lists contact details for the company's board secretary and securities affairs representative Company Contact Information | Position | Name | Contact Address | Phone | Email | | :--- | :--- | :--- | :--- | :--- | | Board Secretary | Ye Yufei | East side of Yongtong Avenue, Rudong Economic Development Zone, Jiangsu Province | 0513-80158003 | apon@apon.com.cn | | Securities Affairs Representative | Huang Xiuxiu | Building 3, No. 1188 Lianhang Road, Minhang District, Shanghai | 021-52260157 | ir@apon.com.cn | [Other Information](index=7&type=section&id=%E5%85%B6%E4%BB%96%E6%83%85%E5%86%B5) The company's contact information, disclosure channels, document storage, and registration status remained unchanged during the reporting period - The company's registered address, office address, website, and email address remained unchanged during the reporting period[17](index=17&type=chunk) - Information disclosure and document storage locations remained unchanged during the reporting period[18](index=18&type=chunk) - The company's registration status remained unchanged during the reporting period[19](index=19&type=chunk) [Key Accounting Data and Financial Indicators](index=8&type=section&id=%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company experienced a significant decline in revenue and net profit, with operating cash flow deteriorating, while total assets and net assets also decreased Key Accounting Data and Financial Indicators (Consolidated Statements) | Indicator | Current Reporting Period (RMB) | Prior Year Period (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 159,166,688.58 | 179,465,240.74 | -11.31% | | Net Profit Attributable to Shareholders of Listed Company | -19,379,092.01 | 8,893,500.73 | -317.90% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains/Losses) | -20,141,917.33 | 5,826,943.34 | -445.67% | | Net Cash Flow from Operating Activities | -47,486,533.36 | -1,956,532.19 | -2,327.08% | | Basic Earnings Per Share (RMB/share) | -0.1537 | 0.0706 | -317.90% | | Diluted Earnings Per Share (RMB/share) | -0.1537 | 0.0706 | -317.90% | | Weighted Average Return on Net Assets | -2.81% | 1.27% | -4.08% | | Indicator | End of Current Reporting Period (RMB) | End of Prior Year (RMB) | Change from End of Prior Year | | :--- | :--- | :--- | :--- | | Total Assets | 832,302,133.09 | 863,485,234.50 | -3.61% | | Net Assets Attributable to Shareholders of Listed Company | 672,087,230.34 | 699,659,442.36 | -3.94% | [Differences in Accounting Data under Domestic and International Accounting Standards](index=8&type=section&id=%E5%A2%83%E5%86%85%E5%A4%96%E4%BC%9A%E8%AE%A1%E5%87%86%E5%88%99%E4%B8%8B%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%B7%AE%E5%BC%82) The company reports no differences in net profit or net assets between international/overseas accounting standards and Chinese accounting standards - The company's financial reports for the reporting period show no differences in net profit and net assets between International Accounting Standards and Chinese Accounting Standards[21](index=21&type=chunk) - The company's financial reports for the reporting period show no differences in net profit and net assets between overseas accounting standards and Chinese Accounting Standards[22](index=22&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=8&type=section&id=%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) Non-recurring gains and losses totaled **RMB 0.7628 million**, primarily from government subsidies and non-current asset disposals, after tax and minority interest adjustments Non-Recurring Gains and Losses Items and Amounts | Item | Amount (RMB) | | :--- | :--- | | Gains or losses from disposal of non-current assets | 40,646.01 | | Government grants recognized in current profit or loss | 1,863,070.61 | | Gains or losses from entrusted investment or asset management | 93,793.05 | | Other non-operating income and expenses apart from the above | -509,321.95 | | Less: Income tax impact | 280,291.67 | | Minority interest impact (after tax) | 445,070.73 | | Total | 762,825.32 | - The company has no other profit or loss items that meet the definition of non-recurring gains and losses, nor does it classify non-recurring gains and losses as recurring gains and losses[25](index=25&type=chunk) [Management Discussion and Analysis](index=10&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section provides an in-depth analysis of the company's operations, financial performance, core competencies, and risks during the reporting period [Company's Main Business Activities During the Reporting Period](index=10&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company focuses on pain and upper airway management, expanding into BCI, facing revenue and profit declines due to market and cost pressures, but continues R&D [Industry Development Overview](index=10&type=section&id=%E8%A1%8C%E4%B8%9A%E5%8F%91%E5%B1%95%E6%83%85%E5%86%B5) The comfort medical market, particularly pain management, nasal care, and BCI, shows significant growth potential driven by increasing patient numbers and supportive national policies - The global pain treatment equipment market is projected to grow at a compound annual growth rate of **13.8%** between 2019 and 2026, reaching a market size of **USD 14.55 billion** by 2026[28](index=28&type=chunk) - China has over **300 million** chronic pain patients, increasing by **10 million to 20 million** annually[29](index=29&type=chunk) - National policies designate Brain-Computer Interface (BCI) as a future industry, with medical applications accounting for **56%** of downstream BCI uses, and a potential global market size of **USD 15 billion to USD 85 billion** for serious medical applications and **USD 25 billion to USD 60 billion** for consumer medical applications[33](index=33&type=chunk)[34](index=34&type=chunk) [Industry Policies and Trends](index=12&type=section&id=%E8%A1%8C%E4%B8%9A%E6%94%BF%E7%AD%96%E5%8F%8A%E8%B6%8B%E5%8A%BF) National policies support pain management and BCI development, including initiatives to improve cancer pain treatment, promote painless childbirth, and encourage non-invasive BCI applications Industry Policies and Trends During the Reporting Period | Related Business | No. | Release Date | Policy Name and Content | Impact on Company | Issuing Authority | | :--- | :--- | :--- | :--- | :--- | :--- | | Pain Management | 1 | March 2025 | "2025 National Medical Quality and Safety Improvement Goals": Improve standardized treatment rate for cancer pain. | Helps improve standardized cancer pain treatment, promoting growth in the company's pain management product business. | National Health Commission | | Pain Management | 2 | June 2025 | "Notice on Comprehensively Promoting Painless Childbirth": By 2027, all secondary and above medical institutions will provide painless childbirth services. | Helps promote painless childbirth, fostering growth in the company's pain management product business. | General Office of the CPC Central Committee, General Office of the State Council | | Pain Management | 3 | July 2025 | "Implementation Plan for Childcare Subsidy System": Provide childcare subsidies for children aged 3 and under. | Helps boost birth rates, promoting growth in the company's painless childbirth product business. | National Health Commission | | Brain-Computer Interface | 1 | March 2025 | "Guidelines for Establishing Medical Service Price Items for Nervous System Categories": Establish price items for invasive/non-invasive brain-computer interfaces. | Promotes rapid clinical application of the company's brain-computer interface technology products. | National Healthcare Security Administration | | Brain-Computer Interface | 2 | July 2025 | "Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry": Encourage the development of non-implantable BCI products and deepen medical health applications. | Promotes rapid commercialization of the company's brain-computer interface technology products. | Ministry of Industry and Information Technology and other seven departments | [Main Business and Product Introduction](index=13&type=section&id=%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1%E5%8F%8A%E4%BA%A7%E5%93%81%E4%BB%8B%E7%BB%8D) The company's core businesses include pain management and nasal/upper airway care, with products like smart infusion pumps and nasal sprays, alongside innovative BCI-related developments - The company's pain management business products include high-precision intelligent microcomputer infusion pumps, wireless pain management systems, internal heat needle therapy devices, low-frequency therapy devices, shockwave therapy devices, and a comprehensive painless childbirth solution of "MCB pulse pump + non-DEHP drug box + obstetrics delivery management information system"[38](index=38&type=chunk)[40](index=40&type=chunk) - Nasal and upper airway management business products include isotonic physiological seawater nasal care spray, hypertonic buffered seawater nasal care spray, weakly acidic buffered physiological seawater nasal care spray, disposable physiological seawater nasal rinse, Minban compound probiotic powder solid beverage, and Xiaonuo eye care spray[46](index=46&type=chunk) - Innovative businesses include anesthesia depth monitors (non-invasive BCI applications), multimodal ADHD behavioral training systems, refractory insomnia anesthesia treatment systems, neuromodulation products (SEEG, VNS, SCS, CNS), and medical aesthetics oral nutrients and optoelectronic instruments[49](index=49&type=chunk)[51](index=51&type=chunk)[52](index=52&type=chunk)[53](index=53&type=chunk) [Operating Performance During the Reporting Period](index=19&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) The company's total revenue decreased by **11.31%**, and net profit turned negative, primarily due to lower sales, increased expenses, and higher credit impairment losses Operating Performance During the Reporting Period | Indicator | Current Reporting Period (RMB 10,000) | Prior Year Period (RMB 10,000) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 15,916.67 | 17,946.52 | -11.31% | | Net Profit Attributable to Shareholders of Listed Company | -1,937.91 | 889.35 | -317.90% | | Pain Management Business Revenue | 9,506.60 | 10,691.76 | -11.08% | | Nasal and Upper Airway Management Business Revenue | 4,680.02 | 5,641.01 | -17.04% | - The decline in net profit is mainly due to lower-than-expected main business revenue, coupled with year-on-year increases in sales expenses, R&D investment, and credit impairment losses[56](index=56&type=chunk)[57](index=57&type=chunk) - The company established an Artificial Intelligence and Brain-Computer Engineering Research Institute, focusing on pain management, anesthesia and sedation, and mental health diagnosis and treatment, to promote R&D, clinical translation, and commercialization of AI medical device technology[51](index=51&type=chunk)[60](index=60&type=chunk) - As of the end of the reporting period, the company held **18** Class III medical device registration certificates and **19** Class II medical device registration certificates, with **200** authorized patents and **95** software copyrights and work copyrights registered[64](index=64&type=chunk) [Analysis of Core Competencies](index=22&type=section&id=%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core strengths lie in its robust R&D, superior product quality, leading market presence, and strategic focus on specialized medical fields and corporate culture - The company possesses core technologies in pain management, including high-precision drug delivery, comprehensive safety monitoring, and pain management information platforms; it pioneered the "sequential therapy" concept in nasal and upper airway management; and it masters non-invasive EEG signal acquisition, processing, and AI algorithms in brain electrical technology[65](index=65&type=chunk) - The company has established a comprehensive quality control system covering R&D, procurement, production, distribution, and after-sales service, obtained ISO9001, ISO13485, and other quality management system certifications, and was recognized as a "Jiangsu Province Advanced Intelligent Factory"[68](index=68&type=chunk)[69](index=69&type=chunk) - The company operates across multiple channels, including clinical, retail pharmacies, and e-commerce platforms, building a comprehensive online marketing network, and has consistently ranked first in sales and brand for light health nasal irrigators on platforms like Tmall and JD.com for many years[70](index=70&type=chunk) - The company adheres to the corporate vision of being a "leader in comfortable medical intelligent equipment," formulating a development strategy to build the top brand in pain management and nasal/upper airway medical devices, and expanding into new businesses such as brain-computer interfaces and AI applications[72](index=72&type=chunk) [Analysis of Main Business](index=25&type=section&id=%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Main business revenue decreased by **11.31%**, while operating costs increased, leading to a **4.97%** decline in gross profit margin, affecting both pain and nasal care products Major Financial Data Year-on-Year Changes | Indicator | Current Reporting Period (RMB) | Prior Year Period (RMB) | Year-on-Year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 159,166,688.58 | 179,465,240.74 | -11.31% | | | Operating Cost | 58,538,084.09 | 57,082,893.49 | 2.55% | | | Sales Expenses | 69,241,795.79 | 59,739,038.78 | 15.91% | | | Administrative Expenses | 33,507,563.50 | 40,880,017.36 | -18.03% | | | Financial Expenses | 973,792.24 | 697,445.14 | 39.62% | Mainly due to a decrease in interest income in the current period. | | Income Tax Expense | -6,476,275.36 | 4,490,921.39 | -244.21% | Mainly due to an increase in deferred income tax assets from deductible losses in the current period. | | R&D Investment | 18,753,949.82 | 15,740,917.42 | 19.14% | | | Net Cash Flow from Operating Activities | -47,486,533.36 | -1,956,532.19 | -2,327.08% | Mainly due to decreased revenue and reduced sales collections. | | Net Cash Flow from Investing Activities | -14,394,020.42 | -92,630,923.50 | 84.46% | Mainly due to a decrease in the purchase of bank wealth management products in the current period. | | Net Cash Flow from Financing Activities | 18,114,956.97 | -2,435,797.76 | 843.70% | Mainly due to an increase in bank borrowings in the current period. | | Net Increase in Cash and Cash Equivalents | -43,765,596.81 | -97,023,253.45 | 54.89% | | Products or Services Accounting for More Than 10% of Revenue | Product or Service | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Profit Margin | Year-on-Year Change in Operating Revenue | Year-on-Year Change in Operating Cost | Year-on-Year Change in Gross Profit Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Medical Device Industry | 159,166,688.58 | 58,538,084.09 | 63.22% | -11.31% | 2.55% | -4.97% | | Pain Management Products | 95,065,989.54 | 30,766,806.46 | 67.64% | -11.08% | 0.06% | -3.61% | | Nasal and Upper Airway Products | 46,800,199.60 | 12,207,845.69 | 73.91% | -17.04% | -7.82% | -2.61% | [Analysis of Non-Core Business](index=26&type=section&id=%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Non-core operations negatively impacted total profit, with credit impairment losses being a significant factor, and these items are not considered sustainable Impact of Non-Core Business on Total Profit | Item | Amount (RMB) | Proportion of Total Profit | Explanation of Cause | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 1,010,455.62 | -3.84% | Investment income recognized under equity method | No | | Credit Impairment Losses | -7,044,332.89 | 26.75% | Provision for bad debts | No | | Non-Operating Income | 4,239.28 | -0.02% | | No | | Non-Operating Expenses | 536,116.65 | -2.04% | Mainly due to external donations in the current period | No | [Analysis of Assets and Liabilities](index=26&type=section&id=%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) Total assets and net assets decreased, with notable changes including reduced cash due to wealth management and operating outflows, and increased short-term borrowings Significant Changes in Asset Composition | Item | Amount at End of Current Period (RMB) | Proportion of Total Assets | Amount at End of Prior Year (RMB) | Proportion of Total Assets | Change in Proportion | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 157,869,661.06 | 18.97% | 201,635,257.87 | 23.35% | -4.38% | Mainly due to the purchase of bank wealth management products and net cash outflow from operating activities in the current period. | | Short-Term Borrowings | 77,800,000.00 | 9.35% | 48,444,832.64 | 5.61% | 3.74% | Mainly due to an increase in bank borrowings in the current period. | | Contract Liabilities | 2,694,730.39 | 0.32% | 16,158,130.10 | 1.87% | -1.55% | Mainly due to the recognition of revenue from customer prepayments from the previous year in the current period. | | Trading Financial Assets | 12,000,000.00 | 1.44% | 1,000,000.00 | 0.12% | 1.32% | Mainly due to the purchase of bank wealth management products in the current period. | | Employee Compensation Payable | 6,239,535.87 | 0.75% | 17,772,346.44 | 2.06% | -1.31% | Mainly due to the accrual of year-end bonuses last year and their payment this year. | - The company had no major overseas assets at the end of the reporting period[83](index=83&type=chunk) - The company had no asset rights restrictions at the end of the reporting period[86](index=86&type=chunk) [Analysis of Investment Status](index=27&type=section&id=%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) Total investment decreased by **3.87%**, with new equity investments in subsidiaries and associates, and a portion of raised funds used for R&D and working capital Investment Amount During the Reporting Period | Indicator | Investment Amount in Current Period (RMB) | Investment Amount in Prior Year Period (RMB) | Change Rate | | :--- | :--- | :--- | :--- | | Total Investment | 92,000,000.00 | 95,701,624.68 | -3.87% | Significant Equity Investments Acquired During the Reporting Period | Name of Investee Company | Main Business | Investment Amount (RMB) | Shareholding Ratio | Investment Profit/Loss in Current Period (RMB) | | :--- | :--- | :--- | :--- | :--- | | Shenzhen Pengrui Brain Science Technology Co., Ltd. | R&D and products such as BCI wearable devices and cognitive behavioral intervention software/hardware systems | 8,250,000.00 | 55.00% | -1,251,009.32 | | Hainan Fangcun Hospital Management Co., Ltd. | Focuses on medical and health services such as ADHD behavioral training therapy | 12,000,000.00 | 7.89% | Not yet invested | | Total | -- | 20,250,000.00 | -- | -1,251,009.32 | - The company has cumulatively used **RMB 262.93 million** in raised funds; the "R&D Center Construction Project" has been completed, the "Industrial Base Upgrade Project" has been terminated, and the remaining raised funds will permanently supplement working capital[92](index=92&type=chunk)[93](index=93&type=chunk)[97](index=97&type=chunk) - During the reporting period, the company's entrusted wealth management transactions amounted to **RMB 92 million**, with an outstanding balance of **RMB 12 million** at period-end[101](index=101&type=chunk) [Significant Asset and Equity Disposals](index=33&type=section&id=%E9%87%8D%E5%A4%A7%E8%B5%84%E4%BA%A7%E5%92%8C%E8%82%A1%E6%9D%83%E5%87%BA%E5%94%AE) The company did not engage in any significant asset or equity disposals during the reporting period - The company did not sell significant assets during the reporting period[103](index=103&type=chunk) - The company did not sell significant equity during the reporting period[104](index=104&type=chunk) [Analysis of Major Holding and Participating Companies](index=34&type=section&id=%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) Key subsidiaries Aipu Science and Shanghai Noseclean experienced year-on-year declines in both operating revenue and net profit during the reporting period Operating Performance of Major Subsidiaries | Company Name | Operating Revenue (RMB) | Operating Profit (RMB) | Net Profit (RMB) | Year-on-Year Change in Operating Revenue | Year-on-Year Change in Operating Profit | Year-on-Year Change in Net Profit | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Aipu Science | 16,954,220.01 | -2,532,206.13 | -2,173,357.93 | -37.62% | -136.42% | -134.67% | | Shanghai Noseclean | 70,018,600.26 | -5,734,906.87 | -2,407,807.87 | -12.80% | -199.92% | -157.15% | [Risks Faced by the Company and Countermeasures](index=34&type=section&id=%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company addresses risks from industry policies, new product R&D, and product quality through strategic adjustments, increased R&D investment, and strict quality control - Industry policy risk: Centralized procurement of infusion pumps will lead to adjustments in business models and changes in the industry competitive landscape, and the company will actively follow policies and adjust its operating and service models[108](index=108&type=chunk) - New product and technology R&D risk: R&D involves high investment, long cycles, and rapid updates; the company will continuously monitor market demand and technological trends, strengthening R&D capabilities and industrialization speed[110](index=110&type=chunk) - Product quality risk: Major products are National Class III and Class II medical devices; the company will strictly adhere to quality regulations, strengthen and improve its quality management system, and prevent product quality incidents[112](index=112&type=chunk) [Registration Form for Investor Relations Activities During the Reporting Period](index=36&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%8E%A5%E5%BE%85%E8%B0%83%E7%A0%94%E3%80%81%E6%B2%9F%E9%80%9A%E3%80%81%E9%87%87%E8%AE%BF%E7%AD%89%E6%B4%BB%E5%8A%A8%E7%99%BB%E8%AE%B0%E8%A1%A8) The company actively engaged with investors through various channels, including online conferences, on-site visits, and participation in exchange platforms - The company hosted multiple institutional investors through online conference calls and on-site visits on January 3, 2025, and February 19, 2025[113](index=113&type=chunk) - The company participated in an online performance briefing via the Shenzhen Stock Exchange's "Interactive Easy Platform" on May 13, 2025[113](index=113&type=chunk) [Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=37&type=section&id=%E5%B8%82%E5%80%BC%E7%AE%A1%E7%90%86%E5%88%B6%E5%BA%A6%E5%92%8C%E4%BC%B0%E5%80%BC%E6%8F%90%E5%8D%87%E8%AE%A1%E5%88%92%E7%9A%84%E5%88%B6%E5%AE%9A%E8%90%BD%E5%AE%9E%E6%83%85%E5%86%B5) The company adopted a market value management system in April 2025 but has not yet disclosed a valuation enhancement plan - The company formulated the "Market Value Management System" in April 2025, which was reviewed and approved by the tenth meeting of the third board of directors[115](index=115&type=chunk) - The company has not yet disclosed a valuation enhancement plan[115](index=115&type=chunk) [Implementation of "Quality and Return Dual Improvement" Action Plan](index=37&type=section&id=%E2%80%9C%E8%B4%A8%E9%87%8F%E5%9B%9E%E6%8A%A5%E5%8F%8C%E6%8F%90%E5%8D%87%E2%80%9D%E8%A1%8C%E5%8A%A8%E6%96%B9%E6%A1%88%E8%B4%AF%E5%BD%BB%E8%90%BD%E5%AE%9E%E6%83%85%E5%86%B5) The company has not yet disclosed its "Quality and Return Dual Improvement" action plan announcement - The company has not yet disclosed the "Quality and Return Dual Improvement" action plan announcement[116](index=116&type=chunk) [Corporate Governance, Environment, and Society](index=38&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) This section details changes in governance, profit distribution, incentive plans, environmental disclosures, and the company's social responsibility initiatives [Changes in Directors, Supervisors, and Senior Management](index=38&type=section&id=%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) There were no changes in the company's directors, supervisors, or senior management during the reporting period - The company's directors, supervisors, and senior management did not change during the reporting period[118](index=118&type=chunk) [Profit Distribution and Capital Reserve Conversion to Share Capital in the Current Reporting Period](index=38&type=section&id=%E6%9C%AC%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E5%8F%8A%E8%B5%84%E6%9C%AC%E5%85%AC%E7%A7%AF%E9%87%91%E8%BD%AC%E5%A2%9E%E8%82%A1%E6%9C%AC%E6%83%85%E5%86%B5) The company plans no cash dividends, bonus shares, or capital reserve conversions for the semi-annual period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period[119](index=119&type=chunk) [Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=38&type=section&id=%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E8%AE%A1%E5%88%92%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E6%88%96%E5%85%B6%E4%BB%96%E5%91%98%E5%B7%A5%E6%BF%80%E5%8A%B1%E6%8E%AA%E6%96%BD%E7%9A%84%E5%AE%9E%E6%96%BD%E6%83%85%E5%86%B5) The company did not implement any equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period[120](index=120&type=chunk) [Environmental Information Disclosure](index=38&type=section&id=%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E6%83%85%E5%86%B5) The company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law - The listed company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law[121](index=121&type=chunk) [Social Responsibility](index=38&type=section&id=%E7%A4%BE%E4%BC%9A%E8%B4%A3%E4%BB%BB%E6%83%85%E5%86%B5) The company actively fulfills its social responsibilities by protecting shareholder, supplier, customer, and employee rights, and engaging in public welfare initiatives - The company strictly adheres to laws, regulations, and its articles of association, improving corporate governance, safeguarding the legitimate rights and interests of shareholders, especially small and medium investors, and communicating with investors through various channels[122](index=122&type=chunk) - The company has established a comprehensive quality control system covering all aspects from R&D, procurement, production, and distribution to after-sales service, and continuously optimizes supply chain management to enhance customer satisfaction[123](index=123&type=chunk) - The company builds a strategically oriented talent growth ecosystem, focuses on employee well-being and humanistic care, and enhances team cohesion through cultural building activities[124](index=124&type=chunk)[125](index=125&type=chunk)[126](index=126&type=chunk) - The company actively participates in the "Huatuo Project Sleep Health Special Action," World Asthma Day free clinics, Children's Day charity events, employs disabled staff, and collaborates with foundations on projects like the "New Year's Day Charity Run" to promote medical inclusivity and support special groups[128](index=128&type=chunk)[129](index=129&type=chunk)[131](index=131&type=chunk) [Significant Matters](index=42&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section covers the fulfillment of commitments, related party transactions, legal proceedings, and other significant events during the reporting period [Commitments Fulfilled by the Company, Actual Controller, Shareholders, Related Parties, Acquirers, and Other Relevant Parties During the Reporting Period and Unfulfilled Commitments as of the End of the Reporting Period](index=42&type=section&id=%E5%85%AC%E5%8F%B8%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E3%80%81%E8%82%A1%E4%B8%9C%E3%80%81%E5%85%B3%E8%81%94%E6%96%B9%E3%80%81%E6%94%B6%E8%B4%AD%E4%BA%BA%E4%BB%A5%E5%8F%8A%E5%85%AC%E5%8F%B8%E7%AD%89%E6%89%BF%E8%AF%BA%E7%9B%B8%E5%85%B3%E6%96%B9%E5%9C%A8%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%B1%A5%E8%A1%8C%E5%AE%8C%E6%AF%95%E5%8F%8A%E6%88%AA%E8%87%B3%E6%8A%A5%E5%91%8A%E6%9C%AB%E8%B6%85%E6%9C%9F%E6%9C%AA%E5%B1%A5%E8%A1%8C%E5%AE%8C%E6%AF%95%E7%9A%84%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9) All commitments made by the company, its controlling shareholder, actual controller, and senior management were strictly fulfilled during the reporting period, with no outstanding unfulfilled commitments - The company, its controlling shareholder, actual controller Wang Ningyu, and its directors, supervisors, and senior management all strictly fulfilled the commitments made during the initial public offering and subsequent refinancing[134](index=134&type=chunk)[135](index=135&type=chunk) - The commitments covered the truthfulness of information disclosure, compensation for investor losses, avoidance of horizontal competition, and measures to mitigate dilution of immediate returns[134](index=134&type=chunk)[135](index=135&type=chunk) - All commitments were fulfilled on time during the reporting period, with no overdue unfulfilled commitments[135](index=135&type=chunk)[136](index=136&type=chunk) [Non-Operating Funds Occupied by Controlling Shareholders and Other Related Parties from the Listed Company](index=44&type=section&id=%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%B3%E8%81%94%E6%96%B9%E5%AF%B9%E4%B8%8A%E5%B8%82%E5%85%AC%E5%8F%B8%E7%9A%84%E9%9D%9E%E7%BB%8F%E8%90%A5%E6%80%A7%E5%8D%A0%E7%94%A8%E8%B5%84%E9%87%91%E6%83%85%E5%86%B5) There were no instances of non-operating funds being occupied by controlling shareholders or other related parties from the listed company during the reporting period - The company had no non-operating funds occupied by controlling shareholders or other related parties during the reporting period[137](index=137&type=chunk) [Irregular External Guarantees](index=44&type=section&id=%E8%BF%9D%E8%A7%84%E5%AF%B9%E5%A4%96%E6%8B%85%E4%BF%9D%E6%83%85%E5%86%B5) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[138](index=138&type=chunk) [Appointment and Dismissal of Accounting Firms](index=44&type=section&id=%E8%81%98%E4%BB%BB%E3%80%81%E8%A7%A3%E8%81%98%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%83%85%E5%86%B5) The company's semi-annual financial report was not audited - The company's semi-annual report was not audited[139](index=139&type=chunk) [Explanation by the Board of Directors and Audit Committee on the "Non-Standard Audit Report" for the Current Reporting Period](index=44&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E3%80%81%E5%AE%A1%E8%AE%A1%E5%A7%94%E5%91%98%E4%BC%9A%E5%AF%B9%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%9C%AC%E6%8A%A5%E5%91%8A%E6%9C%9F%E2%80%9C%E9%9D%9E%E6%A0%87%E5%87%86%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A%E2%80%9D%E7%9A%84%E8%AF%B4%E6%98%8E) This explanation is not applicable for the current reporting period as the company's semi-annual report was not audited [Explanation by the Board of Directors on the "Non-Standard Audit Report" for the Previous Year](index=44&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%AF%B9%E4%B8%8A%E5%B9%B4%E5%BA%A6%E2%80%9C%E9%9D%9E%E6%A0%87%E5%87%86%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A%E2%80%9D%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5%E7%9A%84%E8%AF%B4%E6%98%8E) This explanation is not applicable for the current reporting period [Bankruptcy and Reorganization Matters](index=44&type=section&id=%E7%A0%B4%E4%BA%A7%E9%87%8D%E6%95%B4%E7%9B%B8%E5%85%B3%E4%BA%8B%E9%A1%B9) The company did not experience any bankruptcy or reorganization matters during the reporting period - The company had no bankruptcy or reorganization matters during the reporting period[140](index=140&type=chunk) [Litigation Matters](index=44&type=section&id=%E8%AF%89%E8%AE%BC%E4%BA%8B%E9%A1%B9) The company had no significant litigation or arbitration matters during the reporting period - The company had no significant litigation or arbitration matters during the reporting period[141](index=141&type=chunk) [Penalties and Rectification](index=44&type=section&id=%E5%A4%84%E7%BD%9A%E5%8F%8A%E6%95%B4%E6%94%B9%E6%83%85%E5%86%B5) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[141](index=141&type=chunk) [Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=45&type=section&id=%E5%85%AC%E5%8F%B8%E5%8F%8A%E5%85%B6%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E3%80%81%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E7%9A%84%E8%AF%9A%E4%BF%A1%E7%8A%B6%E5%86%B5) The company, its controlling shareholder, and actual controller maintain good integrity, with no unfulfilled court judgments or overdue large debts - The company, its controlling shareholder, and actual controller Mr. Wang Ningyu have no unfulfilled court judgments or large overdue debts[142](index=142&type=chunk) [Significant Related Party Transactions](index=45&type=section&id=%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) The company had no significant related party transactions, including daily operations, asset/equity transfers, joint investments, or related debt/financial company dealings - The company had no related party transactions related to daily operations during the reporting period[143](index=143&type=chunk) - The company had no related party transactions involving asset or equity acquisitions/disposals during the reporting period[144](index=144&type=chunk) - The company had no related party transactions involving joint external investments during the reporting period[145](index=145&type=chunk) - The company had no related party creditor-debtor relationships during the reporting period[146](index=146&type=chunk) - The company had no deposits, loans, credit lines, or other financial business with related financial companies or financial companies controlled by the company and related parties[147](index=147&type=chunk)[148](index=148&type=chunk) - The company had no other significant related party transactions during the reporting period[149](index=149&type=chunk) [Significant Contracts and Their Performance](index=45&type=section&id=%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E5%85%B6%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) The company had no significant entrustment, contracting, or guarantees, but leased a Shanghai R&D center, paying **RMB 2.2849 million** in rent - The company had no entrustment situations during the reporting period[151](index=151&type=chunk) - The company had no contracting situations during the reporting period[152](index=152&type=chunk) - The company leased Building 3, No. 1188 Lianhang Road, Minhang District, Shanghai, as its Shanghai R&D Center, with a lease term from September 6, 2021, to September 5, 2031, and actually paid **RMB 2.2849 million** in rent during the reporting period[153](index=153&type=chunk) - The company had no significant guarantee situations during the reporting period[154](index=154&type=chunk) - The company had no other significant contracts during the reporting period[155](index=155&type=chunk) [Explanation of Other Significant Matters](index=46&type=section&id=%E5%85%B6%E4%BB%96%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9%E7%9A%84%E8%AF%B4%E6%98%8E) The company made strategic investments in Hainan Fangcun Hospital Management and Changsha Wannuo Medical Technology, and established Apon Zhiyuan Brain Science Technology (Shanghai) Co., Ltd - In June 2025, the company signed an "Capital Increase Agreement" with Hainan Fangcun Hospital Management Co., Ltd., investing **RMB 12 million** to subscribe for **7.89%** of its shares, aiming to promote a new paradigm for digital diagnosis and treatment of pediatric ADHD[156](index=156&type=chunk) - In August 2025, the company's subsidiary Shanghai Noseclean acquired **100%** equity of Changsha Wannuo Medical Technology Co., Ltd., expanding its business in intelligent detection equipment for upper airway diseases[157](index=157&type=chunk)[158](index=158&type=chunk) - In August 2025, the company established a wholly-owned subsidiary, Apon Zhiyuan Brain Science Technology (Shanghai) Co., Ltd., with a registered capital of **RMB 10 million**, focusing on research in brain science, new materials, robotics, artificial intelligence, and other medical device fields[158](index=158&type=chunk) [Significant Matters of Company Subsidiaries](index=47&type=section&id=%E5%85%AC%E5%8F%B8%E5%AD%90%E5%85%AC%E5%8F%B8%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9) There were no other significant matters concerning the company's subsidiaries during the reporting period - The company had no significant matters concerning its subsidiaries during the reporting period[158](index=158&type=chunk) [Share Changes and Shareholder Information](index=48&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section details changes in the company's share capital, restricted shares, and the holdings of major shareholders and management [Share Capital Changes](index=48&type=section&id=%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) Total shares remained unchanged, but restricted shares decreased by **5,472,212** due to executive share lock-up adjustments and expiration of lock-up periods Share Capital Changes | Share Type | Number Before Change (shares) | Proportion Before Change | Increase/Decrease in Current Change (shares) | Number After Change (shares) | Proportion After Change | | :--- | :--- | :--- | :--- | :--- | :--- | | I. Restricted Shares | 43,614,451 | 34.60% | -5,472,212 | 38,142,239 | 30.26% | | II. Unrestricted Shares | 82,433,549 | 65.40% | 5,472,212 | 87,905,761 | 69.74% | | III. Total Shares | 126,048,000 | 100.00% | 0 | 126,048,000 | 100.00% | - The reasons for share changes primarily include the adjustment of executive restricted shares to a **75%** lock-up ratio, and the expiration of the lock-up period for some executive restricted shares held by former Board Secretary Mr. Miao Fei[161](index=161&type=chunk)[162](index=162&type=chunk) [Changes in Restricted Shares](index=49&type=section&id=%E9%99%90%E5%94%AE%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) The total number of restricted shares decreased by **5,472,212**, primarily due to the release of executive restricted shares held by Mr. Wang Ningyu and former executives Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (shares) | Shares Released from Restriction in Current Period (shares) | Restricted Shares at End of Period (shares) | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | Wang Ningyu | 32,345,858 | 5,293,500 | 27,052,358 | Executive Restricted Shares | | Guan Jifeng (Former) | 445,413 | 111,353 | 334,060 | Executive Restricted Shares | | Miao Fei (Former) | 269,435 | 67,359 | 202,076 | Executive Restricted Shares | | Total | 43,614,451 | 5,472,212 | 38,142,239 | -- | [Securities Issuance and Listing](index=49&type=section&id=%E8%AF%81%E5%88%B8%E5%8F%91%E8%A1%8C%E4%B8%8E%E4%B8%8A%E5%B8%82%E6%83%85%E5%86%B5) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[165](index=165&type=chunk) [Number of Shareholders and Shareholding Structure](index=49&type=section&id=%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) As of the reporting period end, the company had **32,425** common shareholders, with major shareholders Wang Ningyu and Zhang Zhihui holding significant stakes, and some shares pledged - The total number of common shareholders at the end of the reporting period was **32,425** households[166](index=166&type=chunk) Shareholding of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Ratio | Number of Shares Held at End of Reporting Period (shares) | Number of Restricted Shares Held (shares) | Number of Unrestricted Shares Held (shares) | Pledged, Marked, or Frozen Status | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Wang Ningyu | Domestic Natural Person | 28.62% | 36,069,811 | 27,052,358 | 9,017,453 | Pledged 8,600,000 shares | | Zhang Zhihui | Domestic Natural Person | 10.46% | 13,179,428 | 9,884,571 | 3,294,857 | Not applicable | | Beijing Zhanghong Private Equity Fund Management Co., Ltd. - Zhanghong Select No. 1 Private Securities Investment Fund | Other | 5.60% | 7,058,000 | 0 | 7,058,000 | Not applicable | - Among the top 10 unrestricted circulating shareholders, Wang Ningyu holds **9,017,453** shares, and Beijing Zhanghong Private Equity Fund Management Co., Ltd. - Zhanghong Select No. 1 Private Securities Investment Fund holds **7,058,000** shares[167](index=167&type=chunk) [Changes in Shareholdings of Directors and Senior Management](index=51&type=section&id=%E8%91%A3%E4%BA%8B%E5%92%8C%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E6%8C%81%E8%82%A1%E5%8F%98%E5%8A%A8) There were no changes in the shareholdings of the company's directors and senior management during the reporting period - The shareholdings of the company's directors and senior management did not change during the reporting period[169](index=169&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=51&type=section&id=%E6%8E%A7%E8%82%A1%E8%82%A1%E4%B8%9C%E6%88%96%E5%AE%9E%E9%99%85%E6%8E%A7%E5%88%B6%E4%BA%BA%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5) There were no changes in the company's controlling shareholder or actual controller during the reporting period - The company's controlling shareholder did not change during the reporting period[170](index=170&type=chunk) - The company's actual controller did not change during the reporting period[170](index=170&type=chunk) [Preferred Share Information](index=51&type=section&id=%E4%BC%98%E5%85%88%E8%82%A1%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[171](index=171&type=chunk) [Bond-Related Information](index=52&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) This section provides information regarding the company's bond-related activities [Bond-Related Information](index=52&type=section&id=%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no bond-related information during the reporting period - The company had no bond-related information during the reporting period[173](index=173&type=chunk) [Financial Report](index=53&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the company's unaudited semi-annual financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity [Audit Report](index=53&type=section&id=%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited[175](index=175&type=chunk) [Financial Statements](index=53&type=section&id=%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's consolidated and parent company financial statements for the first half of 2025, showing declines in assets, negative net profit, and cash flow challenges Consolidated Balance Sheet Major Data | Item | Amount at End of Period (RMB) | Amount at Beginning of Period (RMB) | | :--- | :--- | :--- | | Total Assets | 832,302,133.09 | 863,485,234.50 | | Total Liabilities | 151,620,459.25 | 155,622,128.21 | | Total Owners' Equity | 680,681,673.84 | 707,863,106.29 | Consolidated Income Statement Major Data | Item | H1 2025 (RMB) | H1 2024 (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 159,166,688.58 | 179,465,240.74 | | Operating Profit | -25,797,710.43 | 15,366,649.95 | | Total Profit | -26,329,587.80 | 13,288,533.92 | | Net Profit | -19,853,312.44 | 8,797,612.53 | | Net Profit Attributable to Parent Company Shareholders | -19,379,092.01 | 8,893,500.73 | | Basic Earnings Per Share | -0.1537 | 0.0706 | Consolidated Cash Flow Statement Major Data | Item | H1 2025 (RMB) | H1 2024 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -47,486,533.36 | -1,956,532.19 | | Net Cash Flow from Investing Activities | -14,394,020.42 | -92,630,923.50 | | Net Cash Flow from Financing Activities | 18,114,956.97 | -2,435,797.76 | | Net Increase in Cash and Cash Equivalents | -43,765,596.81 | -97,023,253.45 | [Consolidated Balance Sheet](index=53&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) Consolidated total assets decreased by **3.61%** to **RMB 832 million**, with notable changes in cash, short-term borrowings, and contract liabilities Major Changes in Consolidated Balance Sheet | Item | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | Change Percentage | | :--- | :--- | :--- | :--- | | Monetary Funds | 157,869,661.06 | 201,635,257.87 | -21.69% | | Trading Financial Assets | 12,000,000.00 | 1,000,000.00 | 1100.00% | | Short-Term Borrowings | 77,800,000.00 | 48,444,832.64 | 60.59% | | Contract Liabilities | 2,694,730.39 | 16,158,130.10 | -83.33% | | Deferred Income Tax Assets | 23,474,387.90 | 16,822,874.30 | 39.54% | [Parent Company Balance Sheet](index=55&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) Parent company total assets slightly increased to **RMB 1.037 billion**, with significant changes in accounts receivable, short-term borrowings, and contract liabilities Major Changes in Parent Company Balance Sheet | Item | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | Change Percentage | | :--- | :--- | :--- | :--- | | Monetary Funds | 114,895,241.89 | 135,259,327.93 | -15.06% | | Accounts Receivable | 355,179,540.11 | 332,187,932.74 | 6.92% | | Short-Term Borrowings | 77,800,000.00 | 48,444,832.64 | 60.59% | | Contract Liabilities | 928,361.28 | 13,386,973.65 | -93.07% | | Undistributed Profits | 376,366,709.23 | 362,355,212.95 | 3.87% | [Consolidated Income Statement](index=57&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) Consolidated total operating revenue decreased by **11.31%**, resulting in a net loss, driven by increased sales and R&D expenses, and higher credit impairment losses Major Changes in Consolidated Income Statement | Item | H1 2025 (RMB) | H1 2024 (RMB) | Change Percentage | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 159,166,688.58 | 179,465,240.74 | -11.31% | | Operating Cost | 58,538,084.09 | 57,082,893.49 | 2.55% | | Sales Expenses | 69,241,795.79 | 59,739,038.78 | 15.91% | | R&D Expenses | 18,753,949.82 | 15,740,917.42 | 19.14% | | Credit Impairment Losses | -7,044,332.89 | 605,672.29 | -1262.90% | | Net Profit | -19,853,312.44 | 8,797,612.53 | -325.69% | | Net Profit Attributable to Parent Company Shareholders | -19,379,092.01 | 8,893,500.73 | -317.90% | [Parent Company Income Statement](index=59&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E5%88%A9%E6%B6%A6%E8%A1%A8) Parent company operating revenue decreased by **10.37%**, with net profit declining by **34.30%**, despite a significant increase in investment income Major Changes in Parent Company Income Statement | Item | H1 2025 (RMB) | H1 2024 (RMB) | Change Percentage | | :--- | :--- | :--- | :--- | | Operating Revenue | 129,793,093.29 | 144,806,881.78 | -10.37% | | Sales Expenses | 38,672,885.32 | 23,910,871.11 | 61.74% | | Investment Income | 13,180,811.59 | 79,081.99 | 16566.00% | | Net Profit | 22,204,616.29 | 33,807,442.06 | -34.30% | [Consolidated Cash Flow Statement](index=60&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Consolidated operating cash flow showed a significant net outflow of **RMB 47.4865 million**, while financing cash flow increased substantially Major Changes in Consolidated Cash Flow Statement | Item | H1 2025 (RMB) | H1 2024 (RMB) | Change Percentage | | :--- | :--- | :--- | :--- | | Cash Received from Sales of Goods and Services | 151,019,623.53 | 211,623,528.14 | -28.54% | | Net Cash Flow from Operating Activities | -47,486,533.36 | -1,956,532.19 | -2327.08% | | Net Cash Flow from Investing Activities | -14,394,020.42 | -92,630,923.50 | 84.46% | | Net Cash Flow from Financing Activities | 18,114,956.97 | -2,435,797.76 | 843.70% | | Net Increase in Cash and Cash Equivalents | -43,765,596.81 | -97,023,253.45 | 54.89% | [Parent Company Cash Flow Statement](index=61&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Parent company operating cash flow showed a net outflow of **RMB 44.1195 million**, while investment and financing cash flows turned positive Major Changes in Parent Company Cash Flow Statement | Item | H1 2025 (RMB) | H1 2024 (RMB) | Change Percentage | | :--- | :--- | :--- | :--- | | Cash Received from Sales of Goods and Services | 90,373,417.90 | 105,698,328.58 | -14.41% | | Net Cash Flow from Operating Activities | -44,119,548.72 | -22,623,022.83 | -95.02% | | Net Cash Flow from Investing Activities | 5,712,510.04 | -82,229,591.56 | 106.95% | | Net Cash Flow from Financing Activities | 18,042,952.64 | -1,544,189.88 | 1268.80% | | Net Increase in Cash and Cash Equivalents | -20,364,086.04 | -106,396,804.27 | 80.87% | [Consolidated Statement of Changes in Owners' Equity](index=63&type=section&id=%E5%90%88%E5%B9%B6%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) Consolidated owners' equity decreased by **RMB 27.1814 million**, primarily due to a negative comprehensive income and profit distribution Consolidated Statement of Changes in Owners' Equity | Item | Beginning Balance (RMB) | Change in Current Period (RMB) | Ending Balance (RMB) | | :--- | :--- | :--- | :--- | | Total Owners' Equity | 707,863,106.29 | -27,181,432.45 | 680,681,673.84 | | Total Owners' Equity Attributable to Parent Company | 699,659,442.36 | -27,572,212.02 | 672,087,230.34 | | Minority Interests | 8,203,663.93 | 390,779.57 | 8,594,443.50 | | Total Comprehensive Income | -- | -19,853,312.44 | -- | | Profit Distribution | -- | -8,193,120.01 | -- | [Parent Company Statement of Changes in Owners' Equity](index=67&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E6%89%80%E6%9C%89%E8%80%85%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) Parent company owners' equity increased by **RMB 14.0115 million**, driven by positive comprehensive income partially offset by profit distribution Parent Company Statement of Changes in Owners' Equity | Item | Beginning Balance (RMB) | Change in Current Period (RMB) | Ending Balance (RMB) | | :--- | :--- | :--- | :--- | | Total Owners' Equity | 871,133,367.01 | 14,011,496.28 | 885,144,863.29 | | Total Comprehensive Income | -- | 22,204,616.29 | -- | | Profit Distribution | -- | -8,193,120.01 | -- | [Company Basic Information](index=70&type=section&id=%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) Jiangsu Apon Medical Technology Co., Ltd. was registered in 2016, listed in 2018, with **RMB 126.048 million** registered capital, focusing on pain and upper airway medical devices - The company's registered capital is **RMB 126.048 million**, with a total share capital of **126.048 million** shares[213](index=213&type=chunk) - The company's shares were listed and traded on the Shenzhen Stock Exchange on December 13, 2018[213](index=213&type=chunk) - The company belongs to the medical device industry, primarily engaged in the R&D, production, and sales of medical devices for acute and chronic pain management, and nasal and upper airway management[213](index=213&type=chunk) [Basis of Financial Statement Preparation](index=70&type=section&id=%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E7%9A%84%E7%BC%96%E5%88%B6%E5%9F%BA%E7%A1%80) The financial statements are prepared on a going concern basis, with no significant doubts about the company's ability to continue operations for the next 12 months - The company's financial statements are prepared on a going concern basis[214](index=214&type=chunk) - The company has no matters or circumstances that would cause significant doubt about its ability to continue as a going concern for the 12 months from the end of the reporting period[215](index=215&type=chunk) [Significant Accounting Policies and Estimates](index=70&type=section&id=%E9%87%8D%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96%E5%8F%8A%E4%BC%9A%E8%AE%A1%E4%BC%B0%E8%AE%A1) The financial statements comply with accounting standards, reflecting the company's financial position, with specific policies for financial instruments, inventory, fixed assets, and revenue recognition - The financial statements prepared by the company comply with the requirements of enterprise accounting standards, truly and completely reflecting the company's financial position, operating results, and cash flows[217](index=217&type=chunk) - The company's operating cycle is short, and **12 months** is used as the liquidity classification standard for assets and liabilities[219](index=219&type=chunk) - The company identifies individual accounts receivable exceeding **0.1%** of total assets and greater than **RMB 1 million** as significant accounts receivable[221](index=221&type=chunk) [Taxation](index=93&type=section&id=%E7%A8%8E%E9%A1%B9) The company's main taxes include VAT and corporate income tax, with some subsidiaries enjoying preferential tax rates for high-tech enterprises and small-profit enterprises Major Tax Categories and Rates | Tax Category | Tax Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax | Sales of goods and taxable services revenue, calculated as output tax minus input tax | 13%, 6% | | Property Tax | Assessed at 1.2% of the original value of the property after a one-time deduction of 30%; or 12% of rental income for rental-based assessment | 1.2%, 12% | | Corporate Income Tax | Taxable income | 15%, 20%, 25% | - The company, Aipu Science, and Baishikang have passed high-tech enterprise evaluations and are subject to a reduced corporate income tax rate of **15%** for 2024-2026 or 2022-2024[340](index=340&type=chunk)[341](index=341&type=chunk) - Subsidiaries such as Aizhong Yihui and Aizhong Testing are eligible for small and micro-enterprise corporate income tax preferential policies, where the portion of annual taxable income not exceeding **RMB 1 million** is included in taxable income at **25%** and taxed at a **20%** rate[341](index=341&type=chunk)[342](index=342&type=chunk) - The company and its subsidiaries selling self-developed software products are subject to VAT at the statutory rate, with a refund for the portion of the actual VAT burden exceeding **3%**[342](index=342&type=chunk) [Notes to Consolidated Financial Statement Items](index=94&type=section&id=%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This section details changes in consolidated financial statement items, including decreases in cash and increases in short-term borrowings, alongside revenue and profit declines - Monetary funds at period-end were **RMB 158 million**, a **21.69%** decrease from the beginning of the period, primarily due to the purchase of bank wealth management products and net cash outflow from operating activities[345](index=345&type=chunk) - Trading financial assets at period-end were **RMB 12 million**, an increase of **RMB 11 million** from the beginning of the period, mainly due to the purchase of bank wealth management products during the current period[347](index=347&type=chunk) - Accounts receivable at period-end were **RMB 185 million**, with a bad debt provision of **RMB 26.4731 million**; **RMB 6.3437 million** was provided for bad debts in the current period[354](index=354&type=chunk)[356](index=356&type=chunk)[358](index=358&type=chunk) - Short-term borrowings at period-end were **RMB 77.8 million**, a **60.59%** increase from the beginning of the period, mainly due to an increase in bank borrowings during the current period[444](index=444&type=chunk) - Contract liabilities at period-end were **RMB 2.6947 million**, an **83.33%** decrease from the beginning of the period, mainly due to the recognition of revenue from customer prepayments from the previous year in the current period[452](index=452&type=chunk) - Operating revenue for the current period was **RMB 159 million**, a **11.31%** year-on-year decrease; operating cost was **RMB 58.5381 million**, a **2.55%** year-on-year increase[478](index=478&type=chunk)[479](index=479&type=chunk) - Credit impairment losses for the current period were **-RMB 7.0443 million**, compared to **RMB 0.6057 million** in the previous period, indicating a significant deterioration[494](index=494&type=chunk) - Net cash flow from operating activities was **-RMB 47.4865 million**, a significant outflow increase of **2,327.08%** year-on-year, primarily due to decreased revenue and reduced sales collections[517](index=517&type=chunk)[518](index=518&type=chunk) [Research and Development Expenses](index=119&type=section&id=%E7%A0%94%E5%8F%91%E6%94%AF%E5%87%BA) Total R&D expenses increased by **19.14%** to **RMB 18.7539 million**, all expensed, with employee compensation being the largest component R&D Expense Details | Item | Amount in Current Period (RMB) | Amount in Prior Period (RMB) | | :--- | :--- | :--- | | Employee Compensation | 12,171,131.90 | 8,937,664.33 | | Direct Materials | 939,800.93 | 2,041,767.73 | | Depreciation Expense | 2,424,898.50 | 2,401,195.31 | | Entrusted External R&D Expenses | 1,416,134.91 | 430,000.00 | | Total | 18,753,949.82 | 15,740,917.42 | | Of which: Expensed R&D Expenses | 18,753,949.82 | 15,740,917.42 | [Equity in Other Entities](index=120&type=section&id=%E5%9C%A8%E5%85%B6%E4%BB%96%E4%B8%BB%E4%BD%93%E4%B8%AD%E7%9A%84%E6%9D%83%E7%9B%8A) The company holds equity in various subsidiaries and associates, with notable changes in minority shareholder interests for key non-wholly owned subsidiaries - The company owns several wholly-owned subsidiaries, including Shanghai Noseclean, Aipu Science, and Apon Development, as well as controlling subsidiaries such as Xiaopeng Technology, Jinjiajing, Baishikang, Pengrui Brain Science, and Slanbo[531](index=531&type=chunk) Minority Shareholder Equity in Important Non-Wholly Owned Subsidiaries | Subsidiary Name | Minority Shareholding Ratio | Profit/Loss Attributable to Minority Shareholders in Current Period (RMB) | Minority Shareholder Equity Balance at Period-End (RMB) | | :--- | :--- | :--- | :--- | | Baishikang | 30.00% | 34,645.57 | 1,041,954.80 | | Jinjiajing | 40.00% | 677,779.64 | 2,360,592.90 | | Pengrui Brain Science | 45.00% | -1,023,553.08 | 4,382,651.12 | - The company accounts for its investment in the associate Nantong Yingjue Yihui Venture Capital Center (Limited Partnership) using the equity method, with a carrying amount of **RMB 32.2906 million** at period-end[538](index=538&type=chunk)[541](index=541&type=chunk) [Government Grants](index=122&type=section&id=%E6%94%BF%E5%BA%9C%E8%A1%A5%E5%8A%A9) Government grants recognized in other income totaled **RMB 3.9523 million**, with asset-related deferred income decreasing by **RMB 0.05 million** Liability Items Involving Government Grants | Accounting Account | Beginning Balance (RMB) | New Grants in Current Period (RMB) | Amount Re

Core Viewpoint - The company reported a decline in revenue and a net loss for the first half of 2025 compared to the same period in the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 159 million yuan, representing a year-on-year decrease of 11.31% [1] - The net loss for the first half of 2025 was 19.38 million yuan, contrasting with a net profit of 8.89 million yuan in the same period last year [1]

Group 1 - The core viewpoint of the news is that Aipeng Medical experienced a decline in stock price, dropping by 5.02% to 34.47 CNY per share, with a trading volume of 419 million CNY and a turnover rate of 13.59%, resulting in a total market capitalization of 4.345 billion CNY [1] - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, specializes in the development, production, and sales of medical devices in the fields of pain management and nasal care [1] - The company's main business revenue composition includes pain management products at 61.52%, nasal and upper airway products at 30.55%, other products at 7.55%, and other businesses at 0.37% [1] Group 2 - According to data from the top ten heavy stocks of funds, Beixin Ruifeng Fund holds a significant position in Aipeng Medical, with its health living theme flexible allocation fund (001056) holding 120,000 shares, accounting for 4.43% of the fund's net value, ranking as the tenth largest heavy stock [2] - The fund, established on March 27, 2015, has a latest scale of 89.3779 million CNY, with a year-to-date return of 40.86%, ranking 1022 out of 8194 in its category, and a one-year return of 81.22%, ranking 687 out of 7962 [2] - The fund manager, Pang Wenjie, has been in position for 5 years and 88 days, with the fund's total asset scale at 17 million CNY, achieving a best return of 44.46% and a worst return of -44.25% during his tenure [3]

Group 1 - The core viewpoint of the news is that Aipeng Medical's stock has experienced a decline of 5.02%, with a current price of 34.47 CNY per share and a total market capitalization of 4.345 billion CNY [1] - Aipeng Medical, established on October 30, 2001, specializes in the development, production, and sales of medical devices in the pain management and nasal care sectors [1] - The company's revenue composition includes 61.52% from pain management products, 30.55% from nasal and upper airway products, 7.55% from other products, and 0.37% from other businesses [1] Group 2 - Among the top circulating shareholders of Aipeng Medical, Huaxia Fund's Huaxia Innovation Future Mixed Fund (LOF) has recently entered the top ten, holding 589,700 shares, which is 0.67% of the circulating shares [2] - The Huaxia Innovation Future Mixed Fund (LOF) was established on October 13, 2020, with a latest scale of 2.265 billion CNY and has achieved a year-to-date return of 33.22% [2] - The fund's performance over the past year shows a return of 57.97%, ranking 1810 out of 7962 in its category, while it has experienced a cumulative loss of 31.38% since inception [2]

Group 1 - The stock price of Aipeng Medical reached 36.29 yuan as of August 25, 2025, with an increase of 2.23 yuan, representing a rise of 6.55% from the previous trading day [1] - The company opened at 35.00 yuan, with a highest price of 37.50 yuan and a lowest price of 34.40 yuan, achieving a trading volume of 220,500 lots and a total transaction value of 791 million yuan [1] - Aipeng Medical's main business focuses on medical devices, including sectors such as robotics, specialized and innovative technologies, and influenza [1] Group 2 - The company recently established a wholly-owned subsidiary, Aipeng Zhiyuan Brain Science Technology (Shanghai) Co., Ltd., with a registered capital of 10 million yuan, engaging in artificial intelligence application system integration, intelligent unmanned aerial vehicles, and robotics sales [1] - Aipeng Medical has partnered with the Children's Hospital affiliated with Fudan University to establish a "Brain-Computer Interface Technology Behavioral Therapy Joint Laboratory," further expanding the application of brain-computer interface technology in the medical field [1] Group 3 - On August 25, Aipeng Medical saw a net inflow of main funds amounting to 39.64 million yuan, accounting for 1.33% of its circulating market value [1] - Over the past five days, the main funds experienced a net outflow of 19.60 million yuan, representing 0.66% of the circulating market value [1]

人民财讯8月23日电，8月21日上午，复旦大学附属儿科医院与爱朋医疗（300753）正式签署合作协议， 共同成立"脑机接口技术行为治疗联合实验室"。爱朋医疗董事长王凝宇在公司介绍中强调，作为一家深 耕医疗器械领域的上市公司，爱朋始终坚持围绕临床需求开展技术创新，基于急慢性疼痛管理、鼻腔上 气道轻诊疗的双轨并行的扎实基础上，重点介入脑机接口赛道，布局脑机接口在医疗健康领域中的应 用，尤其聚焦精准麻醉与测痛止痛、儿童注意力缺陷多动障碍(ADHD)、顽固性失眠等方向。公司成立 了"人工智能与脑机工程研究院"，组建跨学科团队，开发了脑机接口与AI结合的多模态行为干预系统。 ...